1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,560 | 5,610 | 25.11. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | LEADS BIOLABS-B (09887): (1) PROPOSED ADOPTION OF THE H SHARE AWARD SCHEME; AND (2) PROPOSED CANCELLATION OF THE SUPERVISORY COMMITTEE AND PROPOSED AMENDMENTS ... | 2 | HKEx | ||
| 10.11. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-024 DOSED FIRST PATIENT IN PHASE II TRIAL OF FIRST-LINE TREATMENT FOR HEPATOCELLULAR CARCINOMA | - | HKEx | ||
| 07.11. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - INCLUSION IN THE MSCI GLOBAL SMALL CAP INDEXES | 1 | HKEx | ||
| 03.11. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - FURTHER ANNOUNCEMENT ON RESEARCH ABSTRACTS ACCEPTED FOR PRESENTATION AT THE 67TH ASH ANNUAL MEETING | 1 | HKEx | ||
| NANJING LEADS BIOLABS Aktie jetzt für 0€ handeln | |||||
| 27.10. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-024 DOSED FIRST PATIENT IN PHASE II TRIAL OF FIRST-LINE TREATMENT FOR BILIARY TRACT CANCER | 1 | HKEx | ||
| 17.10. | LEADS BIOLABS-B (09887): CLARIFICATION ANNOUNCEMENT | 1 | HKEx | ||
| 16.10. | LEADS BIOLABS-B (09887): (REVISED) INSIDE INFORMATION - EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH DIANTHUS FOR LBL-047 | - | HKEx | ||
| 16.10. | LEADS BIOLABS-B (09887): INSIDE INFORMATION - EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH DIANTHUS FOR LBL-047 | - | HKEx | ||
| 16.10. | Dianthus Therapeutics, Inc.: Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for ... | 157 | GlobeNewswire (Europe) | DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function... ► Artikel lesen | |
| 09.10. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT RESEARCH RESULTS OF TWO INNOVATIVE DRUGS TO BE PRESENTED AT THE 67TH ASH ANNUAL MEETING | 2 | HKEx | ||
| 26.09. | LEADS BIOLABS-B (09887): 2025 INTERIM REPORT | - | HKEx | ||
| 22.09. | FDA Approves IND For Nanjing Leads Biolabs' LBL-047, Bispecific Targeting BDCA2 And TACI | 1 | RTTNews | ||
| 22.09. | Nanjing Leads Biolabs Co., Ltd.: First-in-Class Potential! FDA Clears IND Application for LBL-047, an Anti-BDCA2/TACI Bispecific Fusion Protein Developed by Leads Biolabs | 744 | PR Newswire | NANJING, China, Sept. 22, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company", Stock Code: 9887.HK) announced that the U.S.... ► Artikel lesen | |
| 22.09. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT-LBL-047 RECEIVED IND APPROVAL FROM THE U.S. FDA | 1 | HKEx | ||
| 17.09. | LEADS BIOLABS-B (09887): ARTICLES OF ASSOCIATION | 2 | HKEx | ||
| 17.09. | LEADS BIOLABS-B (09887): AMENDMENTS TO THE ARTICLES OF ASSOCIATION | - | HKEx | ||
| 12.09. | Leads Biolabs begins melanoma trial for bispecific antibody | 2 | Investing.com | ||
| 12.09. | Leads Biolabs: Indication Expansion Accelerates: First Patient Dosed in Melanoma Phase 1b/II Trial of Opamtistomig | 124 | PR Newswire | NANJING, China, Sept. 12, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the first... ► Artikel lesen | |
| 12.09. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-024 DOSED FIRST PATIENT IN MELANOMA PHASE IB/II TRIAL OF OPAMTISTOMIG | 1 | HKEx | ||
| 08.09. | LEADS BIOLABS-B (09887): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION ... | - | HKEx |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 71,55 | 0,00 % | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| ARCUTIS BIOTHERAPEUTICS | 30,730 | -0,10 % | Why Shares in Arcutis Biotherapeutics Surged Again This Week | ||
| OLEMA PHARMACEUTICALS | 26,070 | 0,00 % | Biotech-Party! Olema-Aktie explodiert über 136 Prozent - die Hintergründe | Prämie dank Übernahme? Spektakuläre Studienergebnisse? Es ist keine Seltenheit, dass Biotech-Titel aus dem Stand an einem Tag prozentual dreistellig an Wert gewinnen können. Bei Olema Pharmaceuticals... ► Artikel lesen | |
| ARCELLX | 73,00 | 0,00 % | Arcellx: Stifel bekräftigt "Buy"-Rating im Vorfeld der ASH-Konferenz 2025 | ||
| PRAXIS PRECISION MEDICINES | 184,25 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting | ||
| JANUX THERAPEUTICS | 34,740 | 0,00 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
| IMMUNOVANT | 23,950 | 0,00 % | Immunovant, Inc. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 39,720 | +3,06 % | Will Cogent Biosciences' (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So | ||
| QIAGEN | 41,790 | +1,79 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| DYNE THERAPEUTICS | 20,800 | -4,01 % | Dyne Therapeutics: Bernstein hebt Kursziel wegen günstigem Risiko-Ertrags-Verhältnis an | ||
| DISC MEDICINE | 92,53 | 0,00 % | Jefferies bestätigt Kaufempfehlung für Disc Medicine angesichts wichtiger Katalysatoren | ||
| SUMMIT THERAPEUTICS | 17,640 | -1,12 % | Summit Therapeutics: Fortschritte bei Krebsstudien und solide Finanzlage auf Jefferies-Konferenz in London | ||
| APOGEE THERAPEUTICS | 70,92 | 0,00 % | Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results | Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD... ► Artikel lesen | |
| VERA THERAPEUTICS | 29,430 | 0,00 % | Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy | Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46%... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,370 | 0,00 % | Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? |
Das Unternehmen NANJING LEADS BIOLABS CO LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +27,01 % bei einem Aktienkurs von 7,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANJING LEADS BIOLABS CO LTD finden Sie auf Wallstreet Online.